Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)3.04
  • Today's Change0.01 / 0.33%
  • Shares traded1.66m
  • 1 Year change+82.04%
  • Beta1.2021
Data delayed at least 15 minutes, as of Feb 13 2026 08:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Edding Genor Group Holdings Ltd, formerly Genor Biopharma Holdings Ltd, is a company primarily engaged in the biopharmaceuticals business. The Company’s main business is engaged in the discovery, development and commercialization of biopharmaceutical products for human use. The Company’s product pipelines include Lerociclib (GB491), GB261, GB263T, Infliximab (GB242), Coprelotamab (GB221), GB223, Rituximab (GB241) and other products, covering disease fields such as breast cancer, lung cancer, gastrointestinal tumors, and blood tumors. The Company mainly conducts its businesses in the domestic market.

  • Revenue in HKD (TTM)253.70m
  • Net income in HKD22.82m
  • Incorporated2017
  • Employees17.00
  • Location
    Edding Genor Group Holdings Ltd89 Nexus Way, Camana Bay,P.O. Box 31106SHANGHAI 201203ChinaCHN
  • Phone+86 2 161690700
  • Websitehttps://www.eddingpharm.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hua Medicine419.81m1.22bn3.21bn285.002.482.492.557.651.231.230.42531.220.24111.765.712,498,850.0069.99-21.8382.64-25.3152.55--290.30-395.247.00--0.2038--234.02---18.42---17.81--
BioDlink International Co Ltd1.21bn8.22m3.25bn604.00370.463.9235.512.690.01130.01131.671.070.72752.355.491,977,613.000.495-11.370.6586-14.8971.1073.140.6805-24.911.681.830.3519--40.7089.20192.05--27.04--
Medtide Inc-100.00bn-100.00bn3.73bn520.00--2.24----------11.73------------------------4.48--0.0335--31.31--21.00------
Visen Pharmaceuticals-100.00bn-100.00bn3.80bn54.00--3.62----------9.23----------------------------0.0014------26.98------
Qyuns Therapeutics Co Ltd362.84m-217.22m4.64bn337.00--17.88--12.77-0.978-0.9781.631.150.29034.059.141,070,314.00-17.90---28.45--72.44---61.64--1.43-23.190.7466------33.91------
Jacobio Pharmaceuticals Group Co Ltd228.07m-51.70m4.72bn211.00--4.82--20.70-0.0668-0.06680.29481.250.1547--7.97887,438.90-3.51-36.09-4.01-39.58100.0065.67-22.67-283.16----0.1415--145.13--56.64--29.33--
TYK Medicines Inc121.19k-317.21m4.86bn163.00--11.74--40,143.25-0.8554-0.85540.00031.090.0002----792.07-42.68------13.08---263,981.30------0.3215-------1.18------
Laekna Inc0.00-272.08m5.56bn84.00--6.29-----0.7398-0.73980.001.980.00----0.00-27.79---34.25--------------0.1383------31.05------
Edding Genor Group Holdings Ltd253.70m22.82m6.09bn17.0067.631.28175.0824.000.04500.04500.48852.370.1724--5.2110,571,020.001.46-48.631.72-55.1999.5697.888.45-2,303.07----0.0007----73.7192.40---43.79--
MiRXES Holding Co Ltd-100.00bn-100.00bn6.59bn347.00--7.40----------2.99------------------------3.83--0.1682---16.14---33.37------
CARsgen Therapeutics Holdings Ltd95.19m-591.11m8.21bn371.00--7.61--86.28-1.08-1.080.1731.890.04655.137.63203,396.60-28.88-76.51-32.44-89.2550.57---621.16-12,640.866.40--0.0672-------6.73---28.32--
Lepu Biopharma Co Ltd793.33m-200.70m8.37bn546.00--9.40--10.55-0.1173-0.11730.46370.49340.29172.3518.331,593,024.00-8.24-24.70-14.39-37.7188.41---28.26-459.370.5915-5.030.5632--63.21---1,761.77---29.86--
Abbisko Cayman Ltd700.89m169.87m8.64bn226.0049.283.4443.5912.330.26080.26081.113.740.2634--155.742,494,268.006.38-37.376.83-39.08100.00--24.24-625.86----0.0542--2,544.24--106.56--16.58--
Alphamab Oncology890.17m263.68m8.69bn484.0034.144.1025.229.760.26270.26270.89452.190.34920.825423.762,119,453.0010.35-9.9612.30-11.7592.27--29.62-103.284.75--0.1285--192.58--178.99---33.81--
Data as of Feb 13 2026. Currency figures normalised to Edding Genor Group Holdings Ltd's reporting currency: Hong Kong Dollar HKD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.